Scaling up misoprostol to prevent postpartum hemorrhage at home births in Mozambique: A case study applying the ExpandNet/WHO framework by Hobday, K et al.
ORIGINAL ARTICLE
ScalingUpMisoprostol to Prevent PostpartumHemorrhage at
Home Births in Mozambique: A Case Study Applying the
ExpandNet/WHO Framework
Karen Hobday,a Jennifer Hulme,b Ndola Prata,c Páscoa ZualoWate,d Suzanne Belton,a Caroline Homere
Facilitating factors for this community-level scale up in 35 districts included strong government support, local
champions, and a national policy on preventing postpartum hemorrhage (PPH). Challenges included a lack of
a systematic scale-up strategy, limited communication of the PPH policy, a shift from a universal distribution
policy to application of eligibility criteria, difficulties engaging remote traditional birth attendants, and imple-
mentation of a parallel M&E system.
ABSTRACT
Background: Mozambique has a high maternal mortality ratio, and postpartum hemorrhage (PPH) is a leading cause of maternal
deaths. In 2015, the Mozambican Ministry of Health (MOH) commenced a program to distribute misoprostol at the community level in
selected districts as a strategy to reduce PPH. This case study uses the ExpandNet/World Health Organization (WHO) scale-up frame-
work to examine the planning, management, and outcomes of the early expansion phase of the scale-up of misoprostol for the preven-
tion of PPH in 2 provinces in Mozambique.
Methods: Qualitative semistructured interviews were conducted between February and October 2017 in 5 participating districts in
2 provinces. Participants included program stakeholders, health staff, community health workers (CHWs), and traditional birth attend-
ants (TBAs). Interviews were analyzed using the ExpandNet/WHO framework alongside national policy and planning documents and
notes from a 2017 national Ministry of Health maternal, newborn, and child health workshop. Outcomes were estimated using miso-
prostol coverage and access in 2017 for both provinces.
Results: The study revealed a number of barriers and facilitators to scale-up. Facilitators included a supportive political and legal envi-
ronment; a clear, credible, and relevant innovation; early expansion into some Ministry of Health systems and a strong network of
CHWs and TBAs. Barriers included a reduction in reach due to a shift from universal distribution to application of eligibility criteria;
fear of misdirecting misoprostol for abortion or labor induction; limited communication and understanding of the national PPH preven-
tion strategy; inadequate monitoring and evaluation; challenges with logistics systems; and the inability to engage remote TBAs. Lower
coverage was found in Inhambane province than Nampula province, possibly due to NGO support and political champions.
Conclusion: This study identified the need for a formal review of the misoprostol program to identify adaptations and to develop a sys-
tematic scale-up strategy to guide national scale-up.
INTRODUCTION
Each day around the world, approximately 830women die giving birth or due to complications dur-
ing pregnancy, childbirth, and the following weeks.1
Urgent investment in maternal, newborn, and child
health (MNCH) programming is needed in order for
countries to achieve Sustainable Development Goal
(SDG) 3.1—reduce global maternal mortality to less
than 70 per 100,000 live births by 2030.2 Scale up of
high-impact MNCH interventions that reduce maternal
mortality and benefit entire populations is a growing
public health and political priority.3–6
Postpartum hemorrhage (PPH) remains one of the
leading causes of maternal mortality globally and the
number one cause in sub-Saharan Africa.7 Mozambique,
located in Southern Africa, has a high maternal mortality
ratio (MMR) of 489 per 100,000 live births.8 PPH is one of
the main causes of maternal deaths in Mozambique; esti-
mates range from 30.7%9 to 38.0% of maternal deaths.10
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The Ministry of Health (MOH) has prioritized the
prevention of maternal mortality in its Health
Sector Strategic Plan 2014–2019.11
Access to rural health services in Mozambique
is limited by distance, lack of transportation, health
facility coverage, and quality.12,13 In 2013 there
were 0.05 physicians and 0.40 nurses and mid-
wives per 1,000 population.14 This is significantly
below the WHO standard for health worker den-
sity of 2.5 doctors, midwives, and nurses per
1,000 population.15 With inadequate resources to
train and retain health staff,16 Mozambique expe-
riences both brain drain and internal migration.17
Nationally, an estimated 30% of Mozambican
women give birth at home without assistance
from a skilled birth attendant.18 Women who give
birth at home often have support from a traditional
birth attendant (TBA) or family member/friend. In
Inhambane province, a reported 89.1% of women
gave birth with a skilled birth attendant, 3.9%
with a TBA, 6.6% with family/friends, and 0.4%
alone in the 2 years preceding the 2015 Demo-
graphic and Health Survey. In Nampula province,
74.4% of women gave birth with a skilled birth at-
tendant, 11.7% with a TBA, 13.2% with family/
friends, and 0.7% alone.18
Oxytocin, an injectable uterotonic, is the first-
line therapy to prevent and treat PPH and is avail-
able in the majority of health facilities across
Mozambique.19 However, oxytocin must be ad-
ministered by a trained health worker as an injec-
tion and ideally stored in a refrigerator.20 In many
low-income contexts, misoprostol, a heat-stable
tablet that can be used as an alternative uterotonic,
can be administered orally by a community health
worker (CHW) or the woman herself.21 However,
opponents of misoprostol for the prevention of
PPH often fear that it will be used incorrectly or for
abortion.
In 2014, the abortion laws in Mozambique
were changed to permit women to have a safe
abortion up to 12 weeks, up to 16 weeks in cases
of rape or incest, and up to 24 weeks if there are
fetal abnormalities.22 As of 2018, women can
access abortion in primary, secondary, and tertiary
health facilities that have received training and
resources to carry out the procedure.23
In 2009–2010, Bique et al. studied the use of
misoprostol for the prevention of PPH in home
births in Mozambique.24 The pilot study was con-
ducted in response to the MOH request for local
research to establish the safety of using misopros-
tol in the community. Misoprostol was distributed
in advance to pregnant women via MNCH staff
during antenatal care visits and through direct
administration to women from TBAs. Results
revealed that TBAs and women themselves could
safely and effectively administer misoprostol at
home births. In 2011, the results of the pilot were
presented to theMozambiqueMOH,which subse-
quently approved the scale-up of the use of miso-
prostol for the prevention of PPH. For more
information about the role of TBAs and CHWs in
Mozambique, see Box 1.
In 2015, the MOH launched the national
Strategy for the Prevention of Postpartum Hemorrhage
at the Community Level (referred to as the National
PPH Strategy). The first objective of the strategy
was the implementation of the misoprostol pro-
gram, which included advance distribution of
misoprostol towomen during pregnancy and direct
administration by TBAs to women who give birth
in the community to reduce maternal mortality
associated with PPH.29 The National PPH Strategy
included a 2-year general plan of activities with
the intention that each province would develop a
specific action plan for program implementation.
The target was to roll out the misoprostol program
in 35 districts in 10 provinces. TheMOH opted for a
stepwise approach, initially limiting implementa-
tion to 6 districts in 2 provinces—3 in Inhambane
and 3 in Sofala. The intentwas to learn from the ex-
perience of the first 6 districts before further expan-
sion. The second phase of expansion took place in
2016–2017 in 29 districts across 8 provinces. By
June 2017, the misoprostol program was being
implemented in 35 districts. See Figure 1 for a time-
line of events.
There is an urgent need for information about
the process of scale-up of MNCH interventions
that highlights the operational realities countries
experience.30,31 ExpandNet, in collaboration with
the World Health Organization (WHO), defines
scale-up, as the “. . . deliberate efforts to increase
the impact of health service innovations success-
fully tested in pilot or experimental projects so as
to benefit more people and to foster policy and
programme development on a lasting basis.”32
We recognize that moving from pilot to early
expansion and ultimately to population-level
scale-up is a challenging and lengthy process.3
The ExpandNet/WHO framework is a conceptual
tool to guide the analysis of issues to consider in
the development of a scale-up strategy ormanage-
ment of a scale-up process.33 It serves as the basis
for the tool entitled Nine Steps for Developing a
Scaling-Up Strategy,34 which assists stakeholders in
developing a scale-up strategy and to manage the
process. The ExpandNet/WHO framework has
been used to analyze the complex processes of
Postpartum
hemorrhage is
one of themain
causes of
maternal deaths
inMozambique.
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scale-up in a variety of programs and con-
texts.35–37 It addresses 5 main elements of scaling
up: the innovation, environment, user organiza-
tion, resource team, and 5 strategic choice areas
for managing scale-up (Figure 2).34
This article uses the ExpandNet/WHO frame-
work to retrospectively analyze the early phases
of scale-up of the community distribution of miso-
prostol to prevent postpartum hemorrhage in
Mozambique. The aim of this article is to present
a case study that will inform MNCH stakeholders
about the barriers and facilitators in the early
expansion of the misoprostol program and offer
recommendations to stakeholders, both within
Mozambique and internationally, of the key com-
ponents to bring programs to scale.
METHODS
We used a mixed-methods approach to assess
the implementation of the early expansion phase
of scaling up misoprostol in 2 provinces in
Mozambique. The objectives of this study were
to: (1) identify facilitators and barriers to the
BOX 1. The Role of TBAs and CHWs in Mozambique
TBAs play a supportive role for pregnant women, providing assistance during birth and the postpartum period. In Mozambique, TBAs are female
and generally illiterate. They do not receive a salary, and they work with very few resources. For example, they do not receive clean birthing kits.
The majority of Mozambican TBAs do not have formal training or certification in child birth practices or obstetric emergencies.25,26
The TBAs involved in the misoprostol program are affiliated with the participating health facilities. They receive a 3-day training on how to safely
administer misoprostol to women after they give birth, distribute chlorhexidine, and recognize danger signs for referral and safe birth practices. The
training emphasizes the role of TBAs in referring or accompanying women to the health facility to give birth. When a TBA is aware of an impending
birth in the community, she requests a dose of misoprostol from the CHW in her catchment area. The TBA is responsible for safeguarding that dose until
she attends the birth and administers it directly to the woman after she gives birth. TBAs and CHWs do not distribute misoprostol to pregnant women.
CHWs in Mozambique are referred to asAgentes Polivelantes Elementares (APEs) in Portuguese. The vast majority (85%) of APEs are men, mainly
due to the prerequisite of primary school education and the need to undertake a 4- to 5-month training, often outside their community. The APE
program is now actively working to improve gender equality by recruiting more women.27 APEs receive a monthly salary of 1,200 meticals
(approximately US$18 in 2018) and are expected to cover a catchment area of 8 to 25 km from the health facility with which they are affiliated.
Integrated community case management of malaria, pneumonia, and diarrhea is a key component of the work that CHWs undertake. The CHWs receive
a small medical kit and have the authority to provide medicines, including antimalarials, amoxicillin, and zinc.28 In 2016, 4 new products were added to
their role: family planning including administration of injectable contraceptives, vitamin A, chlorhexidine, and distribution of misoprostol to TBAs.
FIGURE 1. The Evolution of the Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Mozambique
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early expansion of the misoprostol program for
the prevention of PPH at the community level,
and (2) examine coverage and use of misoprostol
in the 2 provinces.
The qualitative component of the study applied
a phenomenological approach to understand the
experiences of those involved in Mozambique’s
misoprostol program. Phenomenology is an inter-
pretive approach based on the lived experiences of
people who participated in the phenomenon.38
Data were collected between February and October
2017 inMaputo City and in 2 districts in Inhambane
province and 3 districts in Nampula province. These
provinces were chosen due to geographic region—
Inhambane is located in the southern region, and
Nampula in the northern region of the country.
Inhambane province initiated implementation in
2015, whereas Nampula, one of the provinces
selected during the secondphase of expansion, com-
menced implementation in 2016. Districts were
chosen based on inclusion in the misoprostol pro-
gram, geographic accessibility, and discussions with
provincial and district health authorities.
One-to-one, semistructured qualitative inter-
views were conducted with (1) MNCH national,
provincial, and district stakeholders with experience
working on themisoprostol program; (2) health staff
(MNCH nurses andmidwives, medical chiefs, hospi-
tal directors, pharmacists, and health technicians);
and (3) CHWs (referred to as Agentes Polivalentes
Elementares in Mozambique) and TBAs. In addition,
focus group discussions were conducted separately
with CHWs and TBAs. The ExpandNet/WHO frame-
work and the document entitled 20 Questions for
Developing a Scale-up Case Study30 were used to assist
in the design of the interview guides for stakeholder
and health staff interviews. Focus group discussion
questions for CHWs and TBAs focused on the use
and understanding of the medication and barriers
and facilitators to the misoprostol program. The
interview and focus group discussion guideswere re-
vised with input from the MOH and local research
assistants to ensure questions could be understood
in the local language and were relevant to the
context.
Participants were recruited via purposive sam-
pling based on advice from key stakeholders in the
program and assistance from district health staff
and CHWs. We applied the phenomenological
approach and interviewed a relatively varied
FIGURE 2. ExpandNet/World Health Organization Scale-Up Framework
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sample of participants engaged in various aspects
of the program.We sought to gain a range of expe-
riences rather than selecting an established num-
ber of participants. We contacted 18 MNCH
stakeholders via email or phone to arrange inter-
views. Interviews with 19 health staff were
organized with assistance from district health
authorities who called the health facility in
advance. Fifteen of the stakeholders and all of the
health staff contacted agreed to be interviewed.
CHWs and TBAs were selected with assis-
tance from the district MNCH coordinator who
contacted the CHWs and asked them to come to
the health facility for the interview. Where pos-
sible, the research team would drive to meet the
CHW or TBA at their home or in the community
to conduct the interview. In total, we inter-
viewed 15 CHWs and coordinators and 15 TBAs.
Three CHWs and 4 TBAs who were contacted
were not available to attend an interview due to
prior commitments. Additionally, we conducted
4 FGDs with TBAs in Nampula province and
1 FGD with CHWs in each province. Interviews
were conducted in English, Portuguese, and
local languages where appropriate. The first and
second authors conducted the stakeholder inter-
views. One international and 3 local research
assistants trained in qualitative data collection
methods and ethical protocols conducted inter-
views and focus group discussions at the he-
alth facility and in the field. Interviews were
recorded with permission, transcribed and trans-
lated verbatim into Portuguese, and then trans-
lated to English. Participant numbers were
determined based on obtaining thematic
saturation.
National policy and planning documents were
analyzed alongside notes and observations from a
2017 national MOH MNCH workshop, which
included a review of the misoprostol program.
Notes, policy documents, and qualitative inter-
views were coded and analyzed using NVivo
11 software.
Quantitative data were provided by the pro-
vincial health directors at a national MNCH
workshop. These data were analyzed to esti-
mate coverage of and access to misoprostol in
Inhambane and Nampula provinces from
January through September 2017. We present
descriptive statistics in the results. The resulting
indicators are not based on directly reported
data, but primarily based on calculated, indirect
data estimates leading to some imprecision.
We organized the data according to the
ExpandNet/WHO framework’s planning and
management categories. Categories of the plan-
ning phase included: the environment, the inno-
vation, the user organization, and the resource
team. Management of scale-up was coded into
the 5 strategic choice areas of the ExpandNet/
WHO framework in the following categories: type
of scale-up; dissemination and advocacy; organi-
zational process; costs/mobilization of resources;
and monitoring and evaluation. We also refer-
enced the 20 Questions for Developing a Scale-Up
Case Study30 in coding the transcripts into the plan-
ning and management categories. Results were
further categorized as facilitators and barriers to
scale up, or both. Finally, we included an addi-
tional category to report outcomes, including
coverage and uptake, to assess progress of the
expansion phase. Outcomes were coded into
access, utilization, and logistics systems. We
defined access as the number of women who
delivered with a TBA and received the drug or
who received it in advance during an antenatal
care visit, as a proportion of the estimated number
of expected home births in the catchment area.
Utilization was defined as the number of women
who used misoprostol (i.e., unreturned doses of
misoprostol) as a proportion of the estimated
number of expected home births in the catchment
area.
Ethical clearance was obtained from the
Human Research Ethics Committee at Charles
Darwin University, Australia (HREC 2015–2445),
the Mozambican National Bioethics Committee,
and the MOH. All participants provided informed
consent and none requested to be withdrawn
from the study.
RESULTS
In total, we included in the analysis qualitative
interviews with 15 stakeholders, 19 health staff,
15 CHWs and coordinators, and 15 TBAs; 6 focus
group discussions; and a review of national policy
and planning documents.
Planning the Scale-Up Strategy 2011–2014
The Innovation
In the ExpandNet/WHO framework, the innova-
tion refers to “the health service interventions or
other new practices that are being scaled up.”33
Here, the innovation was the distribution of 600
micrograms of oral misoprostol to pregnant
women through 2 channels: (1) during antenatal
care visits at 28 weeks or greater to women who
meet the criteria for self-administration (Box 2),
or (2) via TBAs who administer it to women
Women received
misoprostol either
directly during an
antenatal care
visit or through
TBAs who
administered it to
women after they
gave birth
at home.
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directly after they give birth at home. The aim of
the innovation was to increase access to miso-
prostol for women who give birth in the commu-
nity to reduce maternal mortality associated with
PPH.
Awomanwhomeets the eligibility criteria at
her antenatal care visit receives information
from the nurse regarding how and when to
take misoprostol and a dose (3 pills in a blister
pack) to safeguard until her labor. Distribution
at the community level occurs between the
TBA and the pregnant woman directly after the
birth of the baby and before the placenta has
been delivered. A CHW provides the TBA with
the misoprostol. CHWs, who are salaried
employees and have access to a bicycle, are the
link between the health facility and TBAs.
Upon request, the CHWs usually receive 3 doses
(9 pills) of misoprostol, which they then distrib-
ute to the TBA(s) in their coverage area
monthly (Figure 3).
Some challenges arose with the flow of distri-
bution. In many cases, CHWs lived further from
the facility than the selected TBAs. CHWs pro-
vided TBAs with the supply of misoprostol, but
the CHWs themselves were not trained or permit-
ted to distribute it to pregnant women. In some
cases, CHWs lived too far from the TBAs, and
they both suggested that the TBAs collect the
misoprostol directly from the health facility during
monthly TBA meetings. A health staff member
from Inhambane province identified this as a
major challenge, saying:
. . . the only constraint that we have had with the TBAs
. . . is the fact that we do not give misol to them directly.
This may have limited distribution of miso-
prostol and reach to remote areas.
During the initial pilot phase, the MOH
shifted from a universal distribution strategy, as
outlined in the National PPH Strategy, to applica-
tion of eligibility criteria (Box 2). This shift was
proposed by the MOH in response to the number
of returned misoprostol doses by women who
gave birth at a health facility and to increase con-
trols on the amount of misoprostol in the com-
munity. The MNCH Sector Wide Approach
(SWAp) Technical Working Group agreed to the
implementation of the eligibility criteria in May
2015. The criteria were adopted to target distri-
bution to women deemed most likely to have
home births, limit unnecessary distribution, and
improve controls on the availability of misopros-
tol in the community.
This shift impacted the amount of misoprostol
required for the program; only 8% of the fore-
casted stock for universal distribution was needed.
The criterion of distance from a facilitywas explicit
(live >8 km from a health facility); however,
interpretations of “far from the facility” varied
widely among health staff. Some nurses and mid-
wives felt that if a woman lived 10 or 15 km away
they would not need misoprostol, as they “should
be able to reach the facility” prior to or while in
labor. Others defined “far” as 20–30 km from the
health facility and thought that only then should
women receive the medication. Some MNCH
stakeholders and health staff based in the field
applauded the additional controls, stating that
misoprostol was ‘flooding’ the communities, which
increased the risk for potentially using misoprostol
for abortion. They also believed that too many
doses were returned to the health facility, which
produced issues for recordkeeping and disposal.
Others criticized the criteria for limiting the num-
ber of womenwho received uterotonic coverage:
So if we want to prevent PPH it has to be covered uni-
versally, it cannot be how it is being done. . . . this strat-
egy has to be reviewed as soon as possible, it must be
universal distribution of misoprostol. (Stakeholder,
Maputo)
A number of stakeholders and health staff in
the MOH national MNCH workshop in October
2017 proposed removing the restrictions to
improve coverage.
Environment
The environment consists of political, sociocul-
tural, and economic factors that impact scale-up
and can present opportunities or challenges to
BOX 2. Eligibility Criteria for Misoprostol Distribution to Pregnant
Women for the Prevention of Postpartum Hemorrhage
A pregnant woman must:
1. Be registered for antenatal care (i.e., have a prenatal health record on file
where misoprostol will be registered)
2. Have reached 28 weeks gestation
She must additionally meet at least 1 of these criteria:
1. Have a history of giving birth at home/outside of the health facility
2. Live more than 8 km from a health facility
3. Be a grand multipara (more than 5 previous births)
4. Have a current or past history of multiple pregnancies
5. Have a history of postpartum hemorrhage
CHWs provided
TBAs with the
supply of
misoprostol, but
the CHWs
themselves were
not trained or
permitted to
distribute it to
pregnant women.
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expansion.33 Several key environmental factors
affected the planning and management phases of
the misoprostol program, namely the country’s fi-
nancial situation, government support for the ini-
tiative, changes to the abortion law, limited
capacity of the health system, and wavering sup-
port for TBAs.
The country’s financial situation was an im-
portant environmental factor. In 2016, the
Mozambican economy experienced a significant
disruption with the revelation of US$1.4 billion
in undisclosed debt. The International Monetary
Fund halted credit to the country and many
international donors, including bilateral govern-
ments, withdrew funding. Economic instability
was cited as a key issue that could impact scalabil-
ity of the misoprostol program. Fiscal spending
became limited across all government institu-
tions.Many health staff described lowmotivation
with the lack of essential consumables, including
gloves for births and vaginal examinations.
Financial constraints were tempered by strong
government support for the program. The MOH
prioritized the prevention of maternal mortality
in the National Health Sector Strategy 2014–2019.11
The distribution of misoprostol for the prevention
of PPH at the health facility is the second objective
listed in the strategy to help reduce the MMR.
International evidence and advocacy efforts from
the Association of Mozambican Obstetricians and
Gynaecologists (AMOG) helped garner the sup-
port needed for the MOH to approve the expan-
sion of the use of misoprostol across selected
districts in Mozambique.
Changes to the abortion law in Mozambique
may have positively influenced the political and
legal settings in which misoprostol for PPH was
introduced. The MOH branded misoprostol for
the prevention of PPH as ‘misol’ to differentiate it
betweenmisoprostol used for induction of labor or
abortion.
Some central and provincial stakeholders were
very supportive of the changes to the legislation
and the impact that they would have on improv-
ing maternal health. For example, a stakeholder
fromMaputo explained:
I think that PPH and safe abortion are very distinct mat-
ters. . . .Andwhenwe think that as a countrywe are lim-
iting the access to misol because we don't want to give
access to providers, to women, in case they can misuse
this misol . . . I think we are just limiting access to life.
FIGURE 3. The Innovation: Misoprostol Distribution Chain
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postpartum
hemorrhage
prevention as
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However, other stakeholders feared that miso-
prostol could be misdirected for abortion or labor
induction and wanted stricter controls:
We need to control the misoprostol because other people
can use it for other purposes like abortions, and they also
know about this use for misoprostol and so we think the
district should distribute it to ensure the best control.
(Health Staff, Inhambane)
The environment also includes the capacity of
the health system to deliver care and services that
impact the success of the planned scale-up.33 The
limited number of qualified health staff in rural
Mozambique resulted in health staff citing they
had inadequate time to include distribution of
misoprostol to their workload. Few additional
resources were provided.
Varying support for working alongside TBAs
also impacted planning for the scale-up of miso-
prostol. Historically, involvement of TBAs within
the formal health sector has been limited in
Mozambique.39 An evaluation of TBA training in
one province in 1999 found no impact on MNCH
outcomes.40 By the year 2000, the MOH shifted
the focus on increasing skilled birth attendants to
achieve Millennium Development Goal (MDG)
5.39 This affected some stakeholders’ acceptance
of the role of TBAs in the misoprostol program,
fearing it would detract from facility-based births:
Some TBAs charge people and promote these births to be
held on her account so she can gain something.
(Stakeholder, Maputo)
Others in favor of TBA participation argued that
the health system did not have the capacity to pro-
vide a skilled birth attendant for every woman due
to a lack of sufficient transport andhuman resources:
That woman who lives 25–30 km from the health unit,
she will go to prenatal consultation until the sixth, sev-
enth month of pregnancy and then she will not go, and
where will she have the baby? She’ll go to the [tradi-
tional] midwife. In my opinion, it is not to say that the
traditional midwife should not help women to give
birth, my opinion is to enable the traditional midwife
to make a clean birth. (Stakeholder, Nampula)
These political, sociocultural, and economic
factors were all essential components that influ-
enced the planning and management of the miso-
prostol program.
The User Organization
The user organization in the ExpandNet/WHO
framework is defined as the institution(s) and/or
organization(s) that are expected to adopt and
implement the innovation at scale.33 The user or-
ganization in this case study is the Mozambican
MOH, specifically the MOH Department of
Women’s and Child Health, which leads the
implementation of the National PPH Strategy and
coordinates monitoring and evaluation (M&E) of
the program. Initially, AMOG was selected as the
intended user organization to support the MOH
to implement the misoprostol program due to
their experience in the pilot phase. Later, the
MOH deemed they were better suited as the sole
user organization given their established infra-
structure and staff. The nationalMOH’s leadership
role greatly facilitated the expansion of the scale-
up as they added to the innovation’s credibility
and acceptability. However, a number of key
national MOH staff members changed positions,
and advisors seconded to the ministry moved on.
This turnover resulted in delays in finalizing the
national PPH strategy and program initiation.
Misoprostol is distributed using the routine
supply chain for MNCH commodities, with the
addition of CHWs as the distributors between the
health facility and the TBAs. In Inhambane prov-
ince, the supply chain experienced weaknesses in
distribution between provincial to district ware-
houses. Misoprostol stock was procured 1 year
prior to the official launch of the program and, as a
result, the remaining shelf life of the initial supply
was shortened by 1 year. (Misoprostol is a some-
what unstable compound that can degrade quickly
when exposed to humidity; it is therefore labeled
with a shorter shelf life thanmost other drugs.)
Provincial MNCH coordinators were requested
to lead the misoprostol programwith support from
the provincial CHW coordinator. Program execu-
tion varied widely depending on the leadership of
the MNCH coordinators at the district level in each
of the 35 implementing districts. Some MNCH
coordinators stated that they felt strongly thatmiso-
prostol was a lifesaving medication and were com-
mitted to the misoprostol program. For example:
I think it will help a lot as we are in the district, yes deliv-
eries outside the maternity are reducing, for sure, but
they continue to occur. This [misoprostol program] is a
great asset for us to avoid maternal deaths in the com-
munity due to postpartum hemorrhage. (Health Staff,
Inhambane)
Other MNCH coordinators were not very sup-
portive and believed it was not “their program”
and instead allocated responsibility to the imple-
menting health facilities.
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MNCHnurses were directly responsible for the
distribution of misoprostol in advance to pregnant
women during antenatal care visits. Some were
discouraged by the additional workload associated
with the program (e.g., having to ensure the
woman met the eligibility criteria, explaining
how to use misoprostol and about possible side
effects, and recording the information in the regis-
ter). Several MNCH nurses believed the program
was a pilot, especially in Inhambane province
where they had experienced multiple hiccups in
the supply chain. This negatively impacted their
motivation to distribute misoprostol during ante-
natal care visits ormonitor the program. Yet quan-
titative results revealed that over 80% of all
misoprostol distributed was distributed to women
in advance during antenatal care visits.
CHWs and TBAs were recruited in coordina-
tion with the CHW program and the MNCH
department. TBAs were recommended either by
the health facility or the CHWs. As a result,
recruited TBAs often lived close to the health facil-
ity. This was also identified as a key factor in the
low coverage experienced in some districts:
To map all TBAs was very difficult for the health facility
and even at the district level. So we said to the MNCH
nurses, “Please select first the ones that are reporting to
you and then identify some that the CHWs recognize . . .”
Those were the 2 inclusion criteria that we used. We
didn't use distance because it was very difficult. . . . I don't
know if we are reaching the TBAs that are really far
away. (Stakeholder, Maputo)
The Resource Team
In the planning phase, keymembers of the resource
team included the MOH, AMOG, the United States
Agency for International Development (USAID),
WHO, Jhpiego’s Maternal and Child Health Int-
egrated Program (MCHIP), and the United Nations
Population Fund (UNFPA). The latter 2 organiza-
tions also provided technical support to the pro-
gram but were not direct implementers. Jhpiego’s
Maternal and Child Survival Project (MCSP), which
followed from MCHIP, provided essential technical
support to the program inNampula and Sofala prov-
inces. AMOGwas involved in the development and
implementation of the pilot, along with the NGO
Venture Strategies Innovation. Using the evidence
from the pilot study, AMOG played a critical role in
advocating the need to scale up misoprostol.41
UNFPA was responsible for the procurement of
stock. The resource team worked together to de-
velop the national PPH strategy.
The resource teammembers also participate in
the MNCH SWAp Technical Working Group. This
group has made some critical decisions surround-
ing the misoprostol program, including the adop-
tion of eligibility criteria for distribution of
misoprostol during antenatal care visits. The
group reportedly met regularly in 2015 and 2016;
however, one informant revealed that the SWAp
had not met during the first 10 months of 2017
due to changes in central government staff. The
resource team’s input and updates regarding pro-
gress on themisoprostol programwas limited dur-
ing this period.
Management of the Scale-Up
Management of the scale-up was categorized as:
type of scale-up; dissemination and advocacy;
organizational process; costs/resource mobiliza-
tion; and monitoring and evaluation.
Type of Scale-Up
The scaling-up strategy refers to the plans and
actions taken to establish the innovation in
policies and programs.33 The ExpandNet/WHO
framework describes 4 types of scale-up: sponta-
neous, diversification, horizontal (expansion or
replication), and vertical (or institutional).33 The
resource team approached the scale-up of miso-
prostol through horizontal scale-up via stepwise
expansion and also to some extent vertical scale-
up through national policy and steps toward
institutionalization.
Horizontal scale-up or expansion occurs when
innovations are replicated in different geographic
locations or are extended to serve larger or new
populations. The innovation should be adapted to
the new context in the additional location(s).
Vertical scale-up occurs when governments reach
a formal agreement to adopt the innovation
nationally or sub-nationally, the adoption is insti-
tutionalized through national planning, policy, or
legal processes, and it is implemented nationally
or sub-nationally, including maintaining provi-
sions to ensure ongoing effective delivery. Di-
mensions from both horizontal and vertical scale-
up need to be incorporated for an innovation to be
sustainable.33
The National PPH Strategy outlines a horizon-
tal scale-up strategy, or the expansion of the inno-
vation across different geographical locations to
reach a larger population33; the expansion of
misoprostol focused on 35 districts in the 10 prov-
inces of Mozambique. Districts were chosen based
on the following criteria: high incidence of home
Mozambique’s
national PPH
strategy outlines a
horizontal scale-
up strategy,
focusing first on 35
districts in 10
provinces.
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births; reasonable access to health facilities for
women who have obstetric complications; exis-
tence of maternal waiting homes; population den-
sity; and the existence of CHWs and TBAs who
work with the health facility.29 In April 2015, the
program was initiated in 6 districts in Sofala and
Inhambane provinces. The rationale was to allow
adequate time for feedback and evaluation before
expanding to the remaining 29 districts. District-
level stakeholders and health staff identified a
number of drawbacks to this strategy, namely,
that implementing in 5 districts per province con-
tributed to confusion about whether this was a
pilot project and to a lack of trained health staff,
as staff are mobile and regularly rotate between
implementing and non-implementing districts.
In June 2016, results from Sofala and
Inhambane were presented at the MNCH SWAp
Technical Working Group meeting in Maputo.
Progress in Sofala was limited to 1 district due
to conflict that impacted both implementation
and M&E. In September 2016, the MOH priori-
tized trainings to take place in the remaining
29 districts. By June 2017, all 35 districts had com-
menced distribution of misoprostol (Figure 2).
Vertical scale-up began simultaneously to hor-
izontal expansion via the development of the
National PPH Strategy and the beginning of insti-
tutionalization into MOH systems, albeit in
selected districts. The National PPH Strategy out-
lined the commitment to incorporating the pro-
gram into routine MOH systems29 (p. 19):
As PPH is a major cause of maternal death, prevention
interventions are part of the larger Ministry of Health
plan to reduce maternal mortality involving several
National Directorates, Departments and Partners.
Thus, during the implementation of the first phase of
this strategy, every effort will be made to ensure that
interventions and their resource needs are integrated
into existing management, funding, coordination and
service delivery mechanisms.
The misoprostol program has yet to be institu-
tionalized. In the early expansion phase, training
was delivered to selectedMOH staff in the selected
districts; UNFPA procured medication and distrib-
uted it through the routine MOH supply chain;
and M&E was developed parallel to the national
health information system.
Dissemination and Advocacy
Dissemination involves methods to promote, com-
municate, and encourage uptake of the innovation
by the user organization.33 In Mozambique, this
included the dissemination of the National PPH
Strategy, communication to provincial health staff,
and cascade training of health staff and CHWs.
The National PPH Strategy was disseminated
from the central to provincial level. The provincial
health authorities were responsible for distribut-
ing the National PPH Strategy and informing the
districts about the program.Memos about the pro-
gram, particularly around stock, were sent from
the central MOH to the provincial health author-
ities. Communication about the national PPH
strategy was a challenge from the beginning, par-
ticularly between provincial and district levels but
also from the district health offices to the health
facilities. Weak flow of information was attributed
to insufficient time to disseminate the strategy and
induct health staff.
In April 2015, the MOH began training
MNCH nurses, CHWs, and TBAs on the distribu-
tion of misoprostol for PPH prevention and safe
delivery methods. The initial trainings took
place in 3 districts in Inhambane and 3 districts
in Sofala provinces in 2015. Cadres in Nampula
province underwent training for 3 days in
August 2016, and distribution of misoprostol
commenced in 5 districts in September 2016. In
total, the resource team trained 36 master train-
ers, 548 provincial trainers, and 1,050 CHW
supervisors at the health facility level.42 Four of
the MNCH nurses interviewed were not for-
mally trained in the program as they were not
working in the district during the training phase.
In Inhambane significantly more CHWs than
TBAs were trained (337 CHWs vs. 47 TBAs),
whereas in Nampula a significant number of
TBAs were trained (189 CHWs and 980 TBAs).
Staff mobility meant that some MNCH staff were
not aware of the program or their role. For
example:
We trained the traditional midwives and a nurse from
each health unit. We know that there is always move-
ment of the nurses, some nurses do not even know what
happened to the misol . . . if we want to have good results
we need to involve all members of the maternal health
team, regardless of being in the maternity or prenatal
consultation. (Health Staff, Nampula)
While nurses and midwives were generally
supportive of the program some hesitated to dis-
tribute misoprostol without formal training.
National-level advocacy played an important
role in the decision to scale-up the innovation
due to divisions among stakeholders about initiat-
ing themisoprostol program. Themain hesitations
were fears that misoprostol would potentially
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detract from facility-based births and/or would be
used for abortion. The MNCH SWAp group
reviewed global studies and the MOH requested
that a pilot be conducted in Mozambique to assess
whether misoprostol could be distributed safely
during antenatal care visits and by TBAs.24 This
review, alongside the results of the Mozambican
pilot and meetings with AMOG and other MNCH
stakeholders about the benefits of misoprostol,
eased fears about controlling the medication in
the community. After discussions, the MOH
agreed to allow the distribution of misoprostol for
the prevention of PPH at the community level.
Organizational Process
Organizing the process of scale-up involves those
responsible for decision making and implementa-
tion.33 In the case of Mozambique, the central
MOHwas the critical decision maker and commu-
nication about the misoprostol program came
from the central to the provincial health author-
ities. The provincial health authorities were then
expected to implement the program in partner-
ship with the district health authorities and health
staff. Central-level government involvement was
a key facilitator for the initial phase of introducing
misoprostol into some parts of the health system.
However, coordination and communication between
the levelswas a barrier. In speaking about the barriers
of managing the system, a stakeholder fromMaputo
revealed:
When you hadmisol at the provincial warehouse then it
was difficult sometimes to get the misol to the district
warehouse. So we had this challenge at the time -
people, values, managing the system; all this was chal-
lenging to improve the system for misol to flow.
The organizational process was also marked by
gradual scale-up starting with only 6 districts in
1 year. Given the delays initiating the program,
rapid rollout in the remaining 29 districts occurred
over just 6 months in response to pressure from
the national MOH to implement in all of the
selected 35 districts. This limited time for monitor-
ing and lessons learned to be considered.
Costs/Resource Mobilization
A budget of US$2.6 million was outlined in the
National PPH Strategy for the first 2 years of the
program.29 The MOH budget covered the fixed
operational and human resources costs for
ongoing delivery of services. Short external donor
grants were the main source of upfront program
funding. Partners within the resource team
provided some financial resources to initiate the
rollout. Originally, USAID planned to provide
both technical support and funding to procure
misoprostol. However, they raised concerns sur-
rounding the supervision and controls of themed-
ication at the community level and requested
further measures to ensure that it would not be
misdirected and used for abortion in the commu-
nity. This led to several months of delays. UNFPA
then agreed to procure misoprostol and became
the major donor, funding both the procurement
and training components. Other partners, includ-
ing Jhpiego, provided funding for training in
2 provinceswhere they supportedMNCHprojects.
In 2015, Jhpiego’s MSCP project also provided
a 1-year grant to AMOG to provide technical sup-
port including supervision. In early 2017, the initial
grant from UNFPA expired and the program con-
tinued on a limited budget. UNFPA received fund-
ing from the UK Department for International
Development (DFID) for 2018–2020 to continue
support for the program. However, limited funds
were allocated to the program outside of those for
procurement, training, and the production of com-
municationmaterials. The lack of available funding
was cited as a major barrier to ensuring the pro-
gram’s sustainability, ongoing supervision, and
evaluation.
Monitoring and Evaluation
The misoprostol M&E system was developed in
parallel to both the national MNCH and CHW
databases and separate to the national health in-
formation system. Data collection on misoprostol
indicators represented additional tasks for the dis-
trict MNCH nurses, who, without a clear system,
were documenting returned doses of misoprostol
by writing data on a separate paper or creating
new columns in the prenatal registers. As a result,
health staff at every level were concerned about
the validity of monthly data collation:
Sometimes we send a message, ‘Colleague tell me there,
when and how many pills you distributed and to the
CHW too,’ she [MNCH nurse] will give you that infor-
mation. Then you add it and you feel that there is some
number missing but you cannot confirm why because
you do not have a concrete instrument for evaluating
the information. (Stakeholder, Provincial Level)
Furthermore, no additional funding was pro-
vided at the provincial or district level to under-
take supervision visits. Between 2015 and 2017,
the MNCH staff alongside partners, including
UNFPA, Jhpiego, and AMOG, conducted several
Themisoprostol
M&E systemwas
developed in
parallel to the
national health
information
system.
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isolated supervision visits, the findings of which
were not widely disseminated. Some provincial
MNCH coordinators were able to monitor along-
side supervisory visits to other programs, but over-
all they felt that time spent was insufficient.
Similarly, some district MNCH coordinators felt
that they did not have the budget, time, or man-
date to supervise the program. In other cases, dis-
trict MNCH nurses were very involved in the
program. Many stakeholders in Maputo and at
the provincial level felt that the lack of M&E was
a major barrier for the sustainability of the
program.
Outcomes
Access and Utilization
Program data, collated by the provincial MNCH
coordinators for the MOH MNCH workshop held
in Maputo in October 2017, were used to estimate
access to and utilization of misoprostol for the first
9 months of 2017 (Table 1). Weaknesses in the
M&E system may have resulted in discrepancies
in both numerators and denominators.
There was large variation in overall access and
utilization between districts and the 2 provinces.
Access to misoprostol in Nampula exceeded
Inhambane province by 17%, and utilization was
much greater in Nampula (91%) than in
Inhambane (23%). Two districts in Nampula
reported over 100% coverage of misoprostol of
women who gave birth at home. Coverage is a
combined measure of both access and utilization
of misoprostol (Table 1).
In Inhambane, we found a number of possible
reasons for low coverage. Health staff restricted
access to misoprostol justified by using the eligibil-
ity criteria. There were also frequent stock-outs.
TBAs and health staff reported that their priority
was to ensure women gave birth at the health fa-
cility. Therefore, TBAs said they administered
misoprostol only to women who had “surprise”
births at home or who had “birthed along the
way” to the health facility, as they indicated they
always encouraged women to give birth at a
health facility.
In Nampula, higher coverage than Inhambane
may be in part attributable to the institutional
memory of the 2009–2010 pilot study: health
staff and CHWs had previous training and were
familiar with and supportive of the program.
Distribution in Nampula started almost 1 year af-
ter Inhambane, such that we may have captured
a period of initial high motivation. Political cham-
pions for misoprostol in Nampula province may
also have positively impacted MNCH health staff
attitudes and willingness to implement the pro-
gram. There were significantly more TBAs trained
and involved in the program than Inhambane
(980 vs. 47, respectively). Further, the program
in Nampula benefited from technical support
from Jhpiego’s MSCP program. See Table 2 for a
comparison of inputs.
Table 3 reveals that from January through
October 2017, MNCH nurses in Nampula distrib-
uted significantly more misoprostol during antena-
tal care visits than in Inhambane (13,602 doses vs.
989, respectively). In both provinces, the majority
of misoprostol was distributed during antenatal
care visits rather than by TBAs. In Inhambane,
194 doses provided to the CHWs were not
accounted for (not provided to the TBA nor
returned to the antenatal care clinic). No data
were available provincially for misoprostol returns
from CHWs or TBAs in Nampula, although we
found individual health centers recording returns.
Logistics System
The initial quantity of misoprostol distributed from
the central to the provincial level was based on the
projection for 100% coverage of home deliveries in
the chosen districts. The introduction of eligibility
criteria in 2015 reduced the number of eligible
women. This led to an excess of misoprostol avail-
able at all levels. Much of this stock was never dis-
tributed, resulting in the expiry and subsequent
incineration of the first wave of commodities.
As of October 2017, in Inhambane 87% of
misoprostol stock was available at the provincial
warehouse, but only 13% had been distributed to
the district or health facility level. In contrast, in
Nampula, almost all of the stock (99%) was dis-
tributed to the district health facilities. Informants
in Inhambane stated that this was due in part to
lack of leadership from some district medical
chiefs to request adequate misoprostol stock, as
well as hesitation by pharmacists to fill requisi-
tions. Further inquiry suggested that pharmacists
and some medical chiefs were hesitant to distrib-
ute what was previously a medication with the
highest restrictions into the community and
feared it would be used for abortion. One health
staff said the medication was kept “locked under
7 doors” due to concerns about the controls in the
community and the maternity units. Some
informants felt that this was one of the largest
barriers to reaching high coverage. Notably, phar-
macists were not included in the dissemination of
the National PPH Strategy.
Access to and
utilization of
misoprostol
varied widely
between districts
and between the
2 provinces.
Themajority of
misoprostol was
distributed during
antenatal care
visits rather than
by TBAs.
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Lack of availability of the commodity at dis-
trict level was a key reason for low coverage
in Inhambane. From September 2016 through
June 2017, misoprostol stock was rationed in
Inhambane with only 5–10 doses distributed per
participating health facility. One district pharma-
cist reported requesting 1,000 doses and received
only 30 doses. Records revealed that other
districts requested very small amounts—30 or
60 pills at a time (sufficient for 10–20 women).
At the time of publication, the MOH had not
yet set a timeline to achieve national scale-up.
Between 2018 and 2020, the MOH will continue
to focus on strengthening the program in the
existing 35 districts and improving M&E mecha-
nisms before further expansion.
DISCUSSION
Our analysis of factors that facilitated scale up of
use of misoprostol to prevent postpartum hemor-
rhage (Table 4) suggest that the political environ-
ment was critical in allowing adoption of the
innovation, benefiting from a high level of
national political support, particularly as reduc-
tion of maternal mortality is the first indicator in
the Mozambique Health Sector Strategic Plan 2014–
2019. The misoprostol program was central to the
National PPH Strategy and facilitated by national
leadership, allowing for inclusion into some of
the MOH infrastructure, systems, and human
resources.
While the MOH led the program planning and
implementation process, misoprostol is being used
TABLE 1. Estimated Access to and Utilization of Misoprostol to Prevent Postpartum Hemorrhage in Inhambane and Nampula
Provinces, Mozambique, January–September 2017
A B C D E F G H I J K
Location
Misoprostol
Distributed
Through
ANC and
TBAs
Misoprostol
Distributed
Minus
Returned
District
Population
(2017)
Annual
Births in
District
(2017)a
Proportion
of Health
Facilities
Enrolled in
Misoprostol
Program
Annual
Births in
Misoprostol
Areasb
Births in
Misoprostol
Areas (First
9 Months
of 2017)c
Home
Births in
Misoprostol
Areas (First
9 Months
of 2017)d
Access to
Misoprostol
at Home
Birthse
Utilization of
Misoprostol
at Home
Birthsf Interpretation
Inhambane Province
Zavala 616 243 163,620 7,363 38% 2,798 2,098 630 98% 39% Excellent access,
poor utilization
Homoine 417 45 131,680 5,926 46% 2,726 2,044 613 68% 7% Fair access, very
poor utilization
Total both
districts
1,033 288 295,300 13,289 42% 5,581 4,143 1243 83% 23% Good access,
poor utilization
Nampula Province
Mecuburi 1,464 840 189,880 8,545 43% 3,674 2,756 827 100%g 100%g Excellent access
and utilization
Erati 2,568 2,034 322,737 14,523 54% 7,842 5,882 1,765 100%g 100%g Excellent access
and utilization
Monapo 1,357 1,039 389,902 17,546 43% 7,545 5,659 1,698 80% 61% Good access,
fair utilization
Total 3
districts
5,389 3,913 902,519 40,613 47% 19,088 14,296 4,289 100%g 91% Excellent access
and utilization
aColumn C * 4.5%.
bColumn E * Column D. The calculation uses a fixed number of residents and assumes population figures are similar across the country, leading to imprecision in
the calculation of access and utilization indicators.
c Column D * 0.75.
dColumn G * 0.30.
eColumn A/Column H.
f Column B/Column H.
g In Mecuburi, access was 100% with 637 remaining doses and 13 additional doses utilized; Erati had 100% access with 803 remaining doses and 269
additional doses utilized. In total, there were 1,440 remaining doses in all 3 districts of Nampula.
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for the prevention of postpartum hemorrhage
only within selected districts and has yet to be
incorporated into routine MOH systems. The
inputs outlined in Table 2 suggest that Jhpiego’s
MCSP program may have been a factor in
Nampula’s success at achieving greater cover-
age, particularly surrounding supervision and
dissemination of information via communi-
cation materials. Institutionalization into the
existing government priorities and health sys-
tem is a critical factor to ensure the program is
supported nationally.43 Until misoprostol is fully
integrated into the national health system and
long-term funding is secured, it may continue
to be viewed as a vertical project.
AMOG and partners employed a successful
advocacy strategy to encourage the MOH and
MNCH SWAp members of the potential high
impact misoprostol had on improving incidence
of PPH. The innovation was equally supported
by international evidence and positive results
from the local pilot study.
The program benefited from the strong exist-
ing network of CHWs and TBAs who provided
the local capacity for implementation and credibil-
ity. However, very few TBAs received misoprostol
for direct distribution (Table 3) compared with the
supply that was provided to the CHWs. This
reveals that there was a weakness in distribution
between CHWs and TBAs in both provinces,
which coincides with qualitative interviews that
found some TBAs were having challenges receiv-
ing misoprostol from CHWs. Furthermore, in
Inhambane significantly more CHWswere trained
versus TBAs, whereas the opposite occurred in
Nampula. This may have been due to the number
of TBAs available and willing to participate in the
misoprostol program.
We provide a number of recommendations for
the MOH and resource team based on the lessons
TABLE 2. Program Inputs Provided in Inhamabane vs. Nampula Provinces, Mozambique
Inputs Inhambane Nampula
Supervision  Ad hoc supervision from health staff when time/resources
permitted
 Routine supervision from Jhpiego MCSP staff
 Some initial supervision visits fromAMOG (funded byMCSP)
Personnel  Health staff strongly believed the misoprostol program was a
pilot project as it was only in selected districts in the province
 Strictly implemented eligibility criteria
 Significantly less misoprostol distributed at ANC (989 doses)
than Nampula
 Fear of misuse limited distribution
 Greater sense of support from health staff as many were
aware of the 2009–2010 pilot and appreciated the
potential misoprostol has to reduce PPH and MMR
 Less sense of a need to limit women due to criteria
 Significantly more distributed at ANC (13,602 doses)
than Inhambane
Champions  Lack of clear champion; MNCH leaders supportive yet con-
strained by lack of resources
 Provincial and district MNCH leaders showed very strong
support for the program and encouraged implementation
Training  Funded by UNFPA; led by trained MOH master trainers,
with UNFPA technical support
 Training imbalanced; targeted more CHWs (337) than TBAs
(47)
 Funded by Jhpiego’s MCSP program; led by AMOG and
MOH with MCSP technical support
 Provided significantly more TBAs with training (980),
providing greater community coverage
Logistics  Challenges distributing stock from province to districts; as
of October 2017, 87% of misoprostol stock remained in
provincial warehouse
 Fewer challenges distributing stock from province to dis-
tricts; only 1% of stock remained in provincial warehouse
as of October 2017
Monitoring and
evaluation
 Parallel system; not integrated in the national health infor-
mation system
 Parallel system; not integrated in the national health in-
formation system
 MCSP provided technical support to develop M&E tools
but they were not adopted at the national level
 No data available provincially on misoprostol returns
from CHWs/TBAs
Abbreviations: AMOG, Association of Mozambican Obstetricians and Gynaecologists; ANC, antenatal care; CHW, community health worker; MCSP,
Maternal and Child Survival Project; M&E, monitoring and evaluation; MMR, maternal mortality ratio; MNCH, maternal, newborn, and child health; MOH,
Ministry of Health; PPH, postpartum haemorrhage; TBA, traditional birth attendant; UNFPA, United Nations Population Fund.
Weaknesses in
distribution of
misoprostol
between CHWs
and TBAs existed
in both provinces.
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learned in the expansion phase (Box 3). There is
clearly a need to allow flexibility in who can dis-
tribute misoprostol. In areas that do not have
TBAs, CHWs could potentially distribute miso-
prostol in advance to women in addition to
advance distribution at antenatal care visits. A
number of studies in Ethiopia, Ghana, Nepal,
Nigeria, and Rwanda have shown that CHWs can
correctly and effectively distribute misoprostol to
women.44–46 TBAs emphasized their role in sup-
porting women to give birth at the health facility.
While positive, this may also have implications for
detracting from safe delivery for women who are
encouraged by TBAs to walk for kilometers in
labor to attempt to reach the health facility and
instead give birth on the side of the road, in transit.
This finding was reported and discussed in more
detail in a related article.47
Overall, the innovation was well-defined,
credible, and adapted to the context. However,
the introduction of restrictive eligibility criteria
further complicated the distribution, limiting
which women were targeted. The distance criteria
was particularly contested by stakeholders and
corroborated by health staff who made arbitrary
decisions about who could or could not feasibly
walk to the health facility while in labor.
Applying eligibility criteria placed emphasis on
facility-based birth instead of increasing utero-
tonic coverage. Due to the difficulty in assessing
who is likely to experience PPH, misoprostol is of-
ten implemented as a population-based universal
prevention method.46,48–50 We recommend revi-
sing the eligibility criteria to increase the number
of women targeted to receive misoprostol in
advance at antenatal care visits.
Four of the nurses and midwives interviewed
had not received training in the misoprostol
program, limiting their involvement and impact.
Fewer than half of all TBAs have been trained on
the use of misoprostol and distance was not con-
sidered in recruitment. As a result, many women
who give birth at home are not receiving miso-
prostol via their TBA. Both of these factors may
have contributed to reduced coverage. We recom-
mend future expansion plans consider implemen-
tation of the misoprostol program within all
health facilities in the selected districts and/or
province and training all health staff including
pharmacists, CHWs, and TBAs to avoid these gaps
in program implementation.
The budget for the misoprostol program was
not fully funded by the government and depended
on external funding. Funding is an essential com-
ponent of catalyzing and sustaining scale-up, and
the nature of short-term donor grants can impede
a government’s capacity to achieve national scale-
up.31 While some organizations assisted with the
costs of training and provided technical support,
the government and partners did not commit suf-
ficient resources for adequate M&E. We recom-
mend the resource team provide funding for
supervision as well as technical support to intro-
duce the misoprostol indicators within the na-
tional health information system to improve effi-
ciency and remove the existing parallel data
collection system. M&E is an element for success-
ful scale-up as outlined in the ExpandNet/WHO
framework and other scale-up literature.31,51
The study revealed disparity between the cov-
erage and access of misoprostol for PPH preven-
tion in Inhambane and Nampula provinces. A
number of factors may have resulted in inflated
numerators. Some CHWs may have maintained
their supplies that had yet to be distributed to
TBAs or returned to the health facilities. One
TABLE 3. Distributed and Returned Misoprostol by Cadre, January–October 2017
Province
Total
Distributed
at ANC
Total
Distributed
by CHWs
Total
Distributed
by TBAs
% of Total
Distributed
to CHWs
Reaching TBAsa
% of Total
Distributed at
ANC via
TBAsb
Returned to
ANC
Returned to
ANC by CHW
or TBA
Inhambane (Homoine,
Zavala districts)
989 325 44 14% 4.4% 201 87
Nampula (Mecurburi,
Erati, Monapo
districts)
13,602 5,578 900 16% 6.6% 1662 Unknown
Abbreviations: ANC, antenatal care; CHW, community health worker; TBA, traditional birth attendant.
a Total distributed by TBAs divided by total distributed by CHWs * 100.
b Total distributed by TBAs divided by total distributed at ANC * 100.
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supervisor found duplication, where both a TBA
and her client had received misoprostol. Given
our finding that there was no space in the MNCH
registers for returned misoprostol (Table 1,
Column B), returned pills may not have been
recorded. We found no evidence of diversion in
this study. Denominators using the estimate of
4.5% of women of reproductive age also likely
underestimate the population, given the high fer-
tility rate in misoprostol target areas.
In 2017, Inhambane reported good access
(83% of expected users received misoprostol) yet
limited utilization (23% of women who received
misoprostol used it). Limited utilization may have
been due to the emphasis on facility births in the
province resulting in women coming to the health
facility to give birth, or perhaps due to limited
communication to the community surrounding
the purpose of misoprostol. The barriers presented
in Table 4 may have impacted the outcomes, spe-
cifically the strict application of the criteria; reten-
tion of trained staff; limited availability of stock at
district level; limited participation of TBAs who
live in more distant rural areas; and minimal sup-
port and resources provided.
On the other hand, high coverage and utiliza-
tion was found in Nampula province, resulting in
high uterotonic coverage at home births. This was
perhaps due to the program being in the first year
of implementation, provincial MNCH champions
who encouraged implementation, a greater num-
ber of participating TBAs, and the additional bene-
fits of technical support from an NGO, particularly
relating to supervision. The original pilot took
place in Nampula, which may have also positively
contributed to increased buy-in from local MNCH
leaders, health staff, CHWs, and TBAs.
The lack of a data collection tool to record
returned misoprostol was a barrier. In Inhambane,
approximately 200 doses provided to CHWs were
unaccounted and there was no data provided
regarding misoprostol returns from CHWs or TBAs
in Nampula. This may be attributed to the follow-
ing: (1) most CHWs kept the medication in their
drug kit for months until the TBA requested the
misoprostol; (2) recording returns was not a formal
process in the antenatal care clinics and not always
recorded; (3) some CHWs directly distributed the
medication to women where there was no TBA
available; or (4) potentially misdirected for abor-
tion or induction; however, there was no evidence
to support this.
The program experienced significant difficul-
ties with the logistics system to distribute the
misoprostol, which should be anticipated and
addressed as part of program planning and M&E.
The majority of misoprostol was distributed in
advance at antenatal care clinics with less than
20% distributed to CHWs to provide to TBAs
(Table 3). The introduction of CHWs as the middle
distributor from the health facility to the TBAs
added an additional step and increased the com-
plexity of the logistics system. Challenges manag-
ing the commodity are common in scale-up
programs.43,52 In Mozambique, this phenomenon
is not unique to misoprostol. A study in Sofala
province found that between 2011 and 2013,
BOX 3. Key Recommendations to the Mozambique Ministry of Health
and Resource Team
The Innovation
 Distribute misoprostol directly to TBAs in situations where there are no CHWs
 In areas without TBAs, allow CHWs to distribute misoprostol in advance to
pregnant women in their catchment area
 Adjust one or more criteria:
* Reduce the timeline to receive misoprostol at ANC from 28 weeks gesta-
tion to 24 weeks
* Reduce the distance to 5 km or measure it in time (e.g., 30 minutes or
1 hour walking)
Dissemination and Advocacy
 Widely disseminate the National PPH Strategy to all health staff including
pharmacists and provincial and district authorities
 Implement a human rights-based approach that advocates to health staff
and communities that women have a right to access misoprostol
 Increase demand in the community by disseminating information about the
benefits of misoprostol, how to safely use it, and where to access it via
CHWs, TBAs, and mobile health units
Organizational Process
 Undertake a formal review of the misoprostol program to identify needed
adaptations and develop a systematic scale-up strategy for the next phases
 Medical chiefs and pharmacists should ensure a consistent supply of miso-
prostol, which meets the demand; review the push/pull system to allow for
timely requisitions of misoprostol
 Train more TBAs and health staff to increase the number of qualified people
who can distribute misoprostol
Costs/Resource Mobilization
 Develop a long-term plan for resource mobilization or redistribution of
resources to fund the misoprostol program and next phase of scale-up
Monitoring and Evaluation
 Provide technical support to introduce the misoprostol indicators within the
national health information system
 Appoint provincial focal persons to support timely reporting and data
analysis
 Provide a formal record/system to accurately record misoprostol provided to
CHWS and returns of misoprostol
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TABLE 4. Facilitators and Barriers to Scaling Up Misoprostol for the Prevention of Postpartum Hemorrhage in
Mozambique, by ExpandNet/WHO Framework
Factors Facilitator Barrier
Planning Phase
Environment
1. Financial situation 
2. Government support including champions 
3. Changes in abortion law 
4. Limited capacity of health system 
5. Wavering support for TBAs 
Innovation
1. Clear, concise, well-defined 
2. Adaptation of criteria 
3. Flow of distribution 
User Organization
1. MOH Central 
2. MOH MNCH health staff  
3. MOH pharmacists 
4. APE (dependent on TBA relationship and distance)  
5. TBA recruitment (close to health facility) 
Resource Team
1. Members  
2. Existence of SWAp MNCH Technical Working Group 
3. SWAp MNCH Technical Working Group irregularity of meetings 
Management Phase
Type of Scale-Up
1. Horizontal (phased expansion) 
2. Limited sites in each district (5 health facilities in selected districts) 
3. Untrained health staff due to mobility 
4. Vertical (institutionalization) 
Dissemination and Advocacy 
1. Development of National PPH Strategy 
2. Communication of PPH Strategy 
3. Training of health staff, APEs, and TBAs  
Organizational Process
1. MOH Central 
2. MOH Provincial  
3. MOH District 
Continued
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85% of district warehouses (n=13) experienced a
stock-out of an essential drug at least once in the
3 annual stock assessments.53 Medicine stock-
outs were strongly associated with distance from
the district warehouse to the health facility.
However, in 2015 a UNFPA assessment found
that 84% of health facilities across Mozambique
had at least 7 essential maternal and reproductive
health medicines, marking an improvement from
the previous assessment of 59% in 2014.54
Concerns thatmisoprostol for the prevention of
PPH would be used by CHWs, TBAs, or women for
abortion impacted implementation. First, the pro-
gram faced initial delays at the central level due to
stakeholder concerns about the potential of incor-
rect use at the community level, and the need for
further supervision delayed initial donor support
for the misoprostol program in Mozambique.41
Second, the MNCH SWAp Technical Working
Group introduced eligibility criteria to impose fur-
ther restrictions and limit distribution at the com-
munity level. Third, there was hesitation by some
provincial and district medical chiefs and pharma-
cists to distribute misoprostol to CHWs and TBAs.
In Mozambique, opponents of misoprostol for the
prevention of PPH often fear that it will be used
incorrectly or for abortion.41 However, our study
found no evidence of confusion about the objective
of misoprostol for the prevention of PPH or diver-
sion of the drug for induction of labor or abortion.
Communication, advocacy, and a human
rights-based approach that reinforces that women
have a right to access this lifesaving medication is
needed fromhealth leaders and champions to shift
this culture of fear and ensure all staff understand
the aims and protocol of the misoprostol program.
The delivery gap—when public health profes-
sionals knowwhat is effective and yet a gap remains
on how the intervention is executed—remains a
critical issue to implementation of health innova-
tions.55 Due to delays initiating the program in the
first 6 districts, roll-out in the remaining 29 dis-
tricts took place relatively quickly, arguably with-
out adequate time for reflection and lessons
learned. We recommend that the resource team
and relevant stakeholders identify needed adapta-
tions and develop a systematic strategy to guide
future scale-up. We further recommend that the
MOH and resource team improve communication
and understanding of the National PPH Strategy
and commit to incorporating the misoprostol pro-
gram into the MOH institutional systems, includ-
ing the national health information system.
Limitations
We interviewed national-level stakeholders and
analyzed national documents and meeting notes.
However, fieldwork was based in only 2 of the 10
provinces undertaking the misoprostol program.
Inhambane province and Nampula province
experienced differences in program inputs, re-
sources, and outcomes. This limits the generaliz-
ability of the study to Mozambique and to other
countries. This case study cannot project the
impact of the program and analysis is limited to
the early expansion phase. It is also important to
note that this was a retrospective analysis of the
planning andmanagement of themisoprostol pro-
gram using the ExpandNet/WHO framework; the
framework was not explicitly utilized by the user
group or resource team in Mozambique as a guide
in their scale-up efforts. Lack of availability of
quantitative data limited analysis and therefore
we were only able to provide estimates of the cov-
erage of misoprostol in the first 9 months of 2017.
Furthermore, data on access to and utilization of
TABLE 4. Continued
Factors Facilitator Barrier
Costs/Resource Mobilization
1. Available Budget 
Outcomes
1. Utilization and access in Nampula province 
2. Utilization and access in Inhambane province 
3. Logistics system 
Abbreviations: APE, Agentes Polivalentes Elementares (community health worker); MNCH, maternal, newborn, and child health;
MOH, Ministry of Health; PPH, postpartum hemorrhage; SWAp, Sector Wide Approach; TBA, traditional birth attendant; WHO,
World Health Organization.
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misoprostol were based primarily on calculated,
indirect estimates, not directly reported data, lead-
ing to imprecision.
CONCLUSION
This study provided a retrospective analysis of the
planning and themanagement of the early expan-
sion of the scale-up ofmisoprostol for PPH preven-
tion. The ExpandNet/WHO framework is a useful
tool to plan, track progress, and allow for continu-
ous learning. While the framework was not used
in the planning ormanagement of themisoprostol
program in Mozambique, the scale-up effort
would have benefited from the development of a
more systematic scale-up strategy during the ini-
tial planning phase.
This case study identified barriers and facili-
tators to scale-up, as well as recommendations
for the misoprostol program rooted in the
ExpandNet/WHO framework. The Mozambican
misoprostol program benefits from political
support, inclusion within the National PPH
Strategy, and integration into some of the MOH
infrastructure, systems, and human resources.
Between 2018 and 2020, the MOH and resource
team will focus on implementation in the exist-
ing 35 districts. This study identifies the need to
have a formal review of the misoprostol program
with the MOH, resource team, and other stake-
holders to identify lessons learned and needed
adaptations, and to develop a systematic scale-
up strategy to guide the continued national
scale-up process.
Acknowledgments: Wewould like to sincerely thank all of the people
who generously gave their time to participate in the study. We
acknowledge the collaboration and support of the Ministry of Health,
provincial and district health authorities, and the Department of
Women’s and Child Health, particularly Dr. Elsa Jacinto. We genuinely
thank Jim Ricca and Jhpiego’s Mozambique MCSP staff for their
assistance to make this study possible. We would also like to extend our
gratitude to the research assistants who worked tirelessly to collect the
data.
Funding: PhD Research Training Program, Australian Government.
Competing Interests: Ms. Hobday reports personal fees from the MCSP
program based at Jhpiego, outside the submitted work.
REFERENCES
1. Maternal mortality: key facts. World Health Organization website.
http://www.who.int/en/news-room/fact-sheets/detail/maternal-
mortality. February 16, 2018. Accessed May 2, 2018.
2. Goal 3: Ensure healthy lives and promote well-being for all at all
ages. United Nations, Sustainable Development Goals website.
http://www.un.org/sustainabledevelopment/health/. Accessed
January 3, 2016.
3. Smith JM, de Graft-Johnson J, Zyaee P, Ricca J, Fullerton J. Scaling
up high-impact interventions: ow is it done? Int J Gynaecol Obstet.
2015;130(suppl 2):S4–S10. CrossRef. Medline
4. Freedman LP, GrahamWJ, Brazier E, et al. Practical lessons from
global safe motherhood initiatives: time for a new focus on imple-
mentation. Lancet. 2007;370(9595):1383–1391. CrossRef.
Medline
5. PATH. The IC2030 Report: Reimagining Global Health: 30 High-
Impact Innovations to Save Lives. Seattle, WA: PATH; 2015. http://
ic2030.org/wp-content/uploads/2015/07/ic2030-report-2015.
pdf. Accessed February 18, 2019.
6. Story WT, LeBan K, Altobelli LC, et al. Institutionalizing community-
focused maternal, newborn, and child health strategies to strengthen
health systems: a new framework for the Sustainable Development
Goal era.Global Health. 2017;13(1):37. CrossRef. Medline
7. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a
WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–
e333. CrossRef. Medline
8. World Health Organization (WHO); UNICEF; UNFPA; World Bank
Group; United Nations Population Division. Trends in Maternal
Mortality: 1990 to 2015: Estimates byWHO, UNICEF, UNFPA,
World Bank Group and the United Nations Population Division.
Geneva: WHO; 2015. https://www.who.int/reproductivehealth/
publications/monitoring/maternal-mortality-2015/en/. Accessed
February 18, 2019.
9. Ministério da Saúde Moçambique. Avaliação de Necessidades em
Saúde Materna e Neonatal em Moçambique (Parte 1). Maputo,
Mozambique: Ministerio da Saude; 2009.
10. David E, Machungo F, Zanconato G, et al. Maternal near miss and
maternal deaths in Mozambique: a cross-sectional, region-wide
study of 635 consecutive cases assisted in health facilities of Maputo
province. BMC Pregnancy Childbirth. 2014;14(1):401. CrossRef.
Medline
11. Ministry of Health, Republic of Mozambique. Health Sector Strategic
Plan 2014-2019. Maputo, Mozambique: Ministry of Health,
Republic of Mozambique. http://www.nationalplanningcycles.org/
sites/default/files/planning_cycle_repository/mozambique/
mozambique_-_health_sector_strategic_plan_-_2014-2019.pdf.
Accessed February 17, 2019.
12. Schwitters A, Lederer P, Zilversmit L, et al. Barriers to health care in
rural Mozambique: a rapid ethnographic assessment of planned
mobile health clinics for ART.Glob Health Sci Pract. 2015;3(1):109–
116. CrossRef. Medline
13. Munguambe K, Boene H, Vidler M, et al. Barriers and facilitators to
health care seeking behaviours in pregnancy in rural communities of
southern Mozambique. Reprod Health. 2016;13(suppl 1):31.
CrossRef. Medline
14. Key country indicators: Mozambique key indicators. World Health
Organization website. http://apps.who.int/gho/data/node.cco.ki-
MOZ?lang=en. Accessed February 18, 2019.
15. World HealthOrganization (WHO). TheWorld Health Report 2006:
Working Together for Health. Geneva: WHO; 2006. https://www.
who.int/whr/2006/en/. Accessed February 18, 2019.
16. Fernandes QF, Wagenaar BH, Anselmi L, Pfeiffer J, Gloyd S, Sherr
K. Effects of health-system strengthening on under-5, infant, and
neonatal mortality: 11-year provincial-level time-series analyses in
Mozambique. Lancet Glob Health. 2014;2(8):e468–e477.
CrossRef. Medline
17. Sherr K, Mussa A, Chilundo B, et al. Brain drain and health work-
force distortions in Mozambique. PLoS One. 2012;7(4):e35840.
CrossRef. Medline
18. Ministerio da Saude Moçambique; Instituto Nacional de Estatística
Moçambique; ICF International. Inquérito de Indicadores de
Imunização, Malária e HIV/SIDA em Moçambique 2015. Maputo,
Mozambique and Rockville, MD: INS, INE, and ICF International;
Scaling Up Misoprostol to Prevent PPH in Mozambique www.ghspjournal.org
Global Health: Science and Practice 2019 | Volume 7 | Number 1 84
2016. https://dhsprogram.com/pubs/pdf/AIS12/AIS12.pdf.
Accessed February 18, 2019.
19. Ministério da Saúde Moçambique; UNFPA. Second Survey of
Availability of Modern Contraceptives and Essential Lifesaving
Maternal/Reproductive Health Medicines in Service Delivery Points.
Report of Mozambique. Maputo, Mozambique: UNFPA; 2012.
20. World Health Organization (WHO). Stability of Injectable Oxytocics
in Tropical Climates: Results of Field Surveys and Simulation Studies
on Ergometrine, Methylergometrine, and Oxytocin. Geneva: WHO;
1993. http://apps.who.int/medicinedocs/en/d/Js2205e/.
Accessed February 18, 2019.
21. World Health Organization (WHO).WHO Recommendations for
the Prevention and Treatment of Postpartum Haemorrhage. Geneva:
WHO; 2012. https://www.who.int/reproductivehealth/
publications/maternal_perinatal_health/9789241548502/en/.
Accessed February 18, 2019.
22. Legal reform in Mozambique widens access to safe abortion care
[news release]. IPAS; 2014. https://www.ipas.org/news/2014/
December/legal-reform-in-mozambique-widens-access-to-safe-
abortion-care. Accessed July 25, 2016.
23. World Health Organization; United Nations. Global Abortion
Policies Database. Country Profile: Mozambique. https://abortion-
policies.srhr.org/country/mozambique/. Last updated May 20,
2018. Accessed May 31, 2018.
24. Bique C, Prata N, Holston M, Moran M, Weinrib R. Community-
Based Prevention of Postpartum Hemorrhage with Misoprostol in
Mozambique: Final Report. Maputo, Mozambique: Venture
Strategies Innovations; 2011. http://bixby.berkeley.edu/wp-
content/uploads/2015/03/VSI_AMOG_Bixby_PSI-Moz-PPH-
Final-Report-2011-05F-ENG.pdf. Accessed February 18, 2019.
25. Gloyd S, Floriano F, Seunda M, Chadreque MA, Nyangezi JM,
Platas A. Impact of traditional birth attendant training in
Mozambique: a controlled study. J Midwifery Womens Health.
2001;46(4):210–216. CrossRef. Medline
26. Munguambe K, Boene H, Vidler M, et al. Barriers and facilitators to
health care seeking behaviours in pregnancy in rural communities of
southern Mozambique. Reprod Health. 2016;13(suppl 1):31.
CrossRef. Medline
27. Ministério da SaúdeMoçambique (MISAU). Estratégia do programa
nacional dos agentes polivalentes elementares (APEs). Maputo,
Mozambique: MISAU; 2016.
28. Chilundo B, Cliff J, Mariano A, Rodriguez D, George A. Relaunch of
the official community health worker programme in Mozambique: is
there a sustainable basis for iCCM policy? Health Policy Plan.
2015;30(suppl 2):ii54–ii64. CrossRef. Medline
29. Libombo A, Bique C, da Luz Vaz M, et al. Strategy for the Prevention
of Postpartum Hemorrhage at the Community Level. Maputo,
Mozambique: Republic of Mozambique, Ministry of Health; 2013.
30. Fajans P, Ghiron L, Khol R, Simmons R. 20 Questions for Developing
a Scaling Up Case Study. Management Systems International,
ExpandNet, andWorld Health Organization; 2007. http://www.
expandnet.net/PDFs/MSI-ExpandNet-IBP%20Case%20Study%
2020%20case%20study%20questions.pdf. Accessed February 17,
2019.
31. Spicer N, Bhattacharya D, Dimka R, et al. ‘Scaling-up is a craft not a
science’: catalysing scale-up of health innovations in Ethiopia, India
and Nigeria. Soc Sci Med. 2014;121:30–38. CrossRef. Medline
32. Simmons R, Fajans P, Ghiron L. Scaling Up Health Service Delivery:
From Pilot Innovations to Policies and Programmes. Geneva: WHO;
2007. https://www.who.int/reproductivehealth/publications/
strategic_approach/9789241563512/en/. Accessed February 18,
2019.
33. World Health Organization (WHO). Practical Guidance for Scaling
Up Health Service Innovations. Geneva:WHO; 2009. https://www.
who.int/reproductivehealth/publications/strategic_approach/
9789241598521/en/. Accessed February 18, 2019.
34. World Health Organization (WHO); ExpandNet.Nine Steps for
Developing a Scaling-Up Strategy. Geneva: WHO; 2010. https://
www.who.int/reproductivehealth/publications/strategic_
approach/9789241500319/en/. Accessed February 18, 2019.
35. Ghiron L, Shillingi L, Kabiswa C, et al. Beginning with sustainable
scale up in mind: initial results from a population, health and envi-
ronment project in East Africa. Reprod Health Matters. 2014;22
(43):84–92. CrossRef. Medline
36. Keyonzo N, Nyachae P, Kagwe P, et al. From project to program:
Tupange’s experience with scaling up family planning interventions
in urban Kenya. Reprod Health Matters. 2015;23(45):103–113.
CrossRef. Medline
37. Chandra-Mouli V, Gibbs S, Badiani R, Quinhas F, Svanemyr J.
Programa Geração Biz, Mozambique: how did this adolescent
health initiative grow from a pilot to a national programme, and
what did it achieve? Reprod Health. 2015;12(1):12. CrossRef.
Medline
38. Schwandt TA. Three epistemological stances for qualitative inquiry:
interpretivism, hermeneutics and social constructivism. In: Denzin
NK, Lincoln YS, eds. The Handbook of Qualitative Research. 2nd ed.
Thousand Oaks, CA: Sage Publications; 2000:189–213.
39. Ministério da Saúde Moçambique.National Plan for Health Human
Resources Development (NPHHRD) 2008–2015. Maputo,
Mozambique: Ministry of Health National Directorate of Human
Resources; 2008. http://www.nationalplanningcycles.org/sites/
default/files/country_docs/Mozambique/hrhplan_english.pdf.
Accessed February 18, 2019.
40. Gloyd S, Floriano F, Seunda M, Chadreque MA, Nyangezi JM,
Platas A. Impact of traditional birth attendant training in
Mozambique: a controlled study. J Midwifery Womens Health.
2001;46(4):210–216. CrossRef. Medline
41. African Strategies for Health (ASH).Misoprostol Policy and Scale-Up
for the Prevention of Postpartum Hemorrhage in Mozambique:
Country Report. Arlington, VA: ASH; 2016. https://www.msh.org/
sites/msh.org/files/misoprostol_policy_and_scale_up_in_
mozambique_aug_2016.pdf. Accessed February 18, 2019.
42. Ministério da Saúde Moçambique. Apresentacao Ponto da situacao
das novas intervencoes. Maputo, Mozambique: Ministério da
Saúde; 2017.
43. Wells E, Coeytaux F, Azasi E, et al. Evaluation of different models of
access to misoprostol at the community level to improve maternal
health outcomes in Ethiopia, Ghana, and Nigeria. Int J Gynaecol
Obstet. 2016;133(3):261–265. CrossRef. Medline
44. Wells E, Coeytaux F, Azasi E, et al. Scaling Up Access to Misoprostol
at the Community Level to Improve Maternal Health Outcomes in
Ethiopia, Ghana, and Nigeria: Findings From an Evaluation of
Different Models. Public Health Institute; 2014. http://www.
dialogue4health.org/uploads/resources/SynthesisFINAL.pdf.
Accessed February 18, 2019.
45. Dao B, Ngabo F, Zoungrana J, et al. Increasing access to prevention
of postpartum hemorrhage interventions for births in health facilities
and at home in four districts of Rwanda. Afr J Reprod Health.
2015;19(4):58–67. Medline
46. Rajbhandari S, Hodgins S, Sanghvi H, McPherson R, Pradhan YV,
Baqui AH; Misoprostol Study Group. Expanding uterotonic protec-
tion following childbirth through community-based distribution of
misoprostol: operations research study in Nepal. Int J Gynaecol
Obstet. 2010;108(3):282–288. CrossRef. Medline
47. Hobday K, Hulme J, Homer C, ZualoWate P, Belton S, Prata N. “My
job is to get pregnant women to the hospital”: a qualitative study of
the role of traditional birth attendants in the distribution of misopros-
tol to prevent post-partum haemorrhage in two provinces in
Mozambique. Reprod Health. 2018;15(1):174. CrossRef. Medline
Scaling Up Misoprostol to Prevent PPH in Mozambique www.ghspjournal.org
Global Health: Science and Practice 2019 | Volume 7 | Number 1 85
48. Mobeen N, Durocher J, Zuberi NF, et al. Administration of miso-
prostol by trained traditional birth attendants to prevent postpartum
haemorrhage in homebirths in Pakistan: a randomised placebo-
controlled trial. BJOG. 2011;118(3):353–361. CrossRef. Medline
49. Webber GC, Chirangi B. Women’s health in women’s hands: a pilot
study assessing the feasibility of providing women with medications
to reduce postpartum hemorrhage and sepsis in rural Tanzania.
Health CareWomen Int. 2014;35(7-9):758–770. CrossRef. Medline
50. Sanghvi H, Ansari N, Prata NJV, Gibson H, Ehsan AT, Smith JM.
Prevention of postpartum hemorrhage at home birth in Afghanistan.
Int J Gynaecol Obstet. 2010;108(3):276–281. CrossRef. Medline
51. Fixsen A, Lundgren R, Igras S, Jennings V, Sinai I.Monitoring and
Evaluating Scale-Up of Health System Innovations. Washington, DC:
Institute for Reproductive Health, Georgetown University; 2013.
http://irh.org/wp-content/uploads/2013/09/ME_Scale_Up_
Briefing_Paper_Final.pdf. Accessed February 18, 2019.
52. Orobaton N, Abdulazeez J, Abegunde D, et al. Implementing at-
scale, community-based distribution of misoprostol tablets to mothers
in the third stage of labor for the prevention of postpartum
haemorrhage in Sokoto State, Nigeria: early results and lessons
learned. PLoS One. 2017;12(2):e0170739. CrossRef. Medline
53. Wagenaar BH, Gimbel S, Hoek R, et al. Stock-outs of essential
health products in Mozambique - longitudinal analyses from
2011 to 2013. Trop Med Int Health. 2014;19(7):791–801.
CrossRef. Medline
54. UNFPA East and Southern Africa (ESARO). Sixth Survey on
Availability of Modern Contraceptives and Essential Life-Saving
Maternal/Reproductive Health Medicines in Health Facilities of
Mozambique. Maputo, Mozambique: UNFPA ESARO; 2017.
https://esaro.unfpa.org/en/publications/sixth-survey-availability-
modern-contraceptives-and-essential-life-saving. Accessed
February 18, 2019.
55. World Health Organization (WHO). Bridging the “Know–Do”Gap:
Meeting on Knowledge Translation in Global Health. Geneva:
WHO; 2006. https://www.measureevaluation.org/resources/
training/capacity-building-resources/high-impact-research-
training-curricula/bridging-the-know-do-gap.pdf. Accessed
February 18, 2019.
Peer Reviewed
Received: December 3, 2018; Accepted: February 3, 2019
Cite this article as: Hobday K, Hulme J, Prata N,Wate PZ, Belton S, Homer C. Scaling up misoprostol to prevent postpartum hemorrhage at home births
in Mozambique: a case study applying the ExpandNet/WHO framework. Glob Health Sci Pract. 2019;7(1):66-86. https://doi.org/10.9745/GHSP-
D-18-00475
© Hobday et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited. To view a
copy of the license, visit http://creativecommons.org/licenses/by/4.0/. When linking to this article, please use the following permanent link: https://
doi.org/10.9745/GHSP-D-18-00475
Scaling Up Misoprostol to Prevent PPH in Mozambique www.ghspjournal.org
Global Health: Science and Practice 2019 | Volume 7 | Number 1 86
